SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2014 / Cilt: 62 - Sayı: 2

Akciğer hastalıklarında pnömokok hastalıkları riski ve erişkin aşılamasının önemi

Murat AKOVA
Esra UZASLAN
Arzu MİRİCİ
Oğuz KILINÇ
Aykut ÇİLLİ
Mustafa Hikmet ÖZHAN
Abdullah SAYINER
Pages
154–159
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

AKOVA, M., UZASLAN, E., MİRİCİ, A., KILINÇ, O., ÇİLLİ, A., ÖZHAN, M. H., SAYINER, A. (2022). Akciğer hastalıklarında pnömokok hastalıkları riski ve erişkin aşılamasının önemi. Tüberküloz ve Toraks, Cilt: 62 - Sayı: 2, 154–159. https://ajindex.com/articles/618624

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Ludwig E, Bonanni P, Rohde G, Sayiner A, Torres A. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012
  2. valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008
  3. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012
  4. Jansen AG, Rodenburg GD, de Greeff SC, Hak E, Veenhoven RH, Spanjaard L, et al. Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits. Vaccine 2009
  5. Centers for Disease Control and Prevention (CDC) 2011. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2010. 6. Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997
  6. Centers for Disease Control and Prevention (CDC)
  7. Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010
  8. Kyaw MH, Rose CE Jr, Fry AM, Singleton JA, Moore Z, Zell ER, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005
  9. Vila-Corcoles A, Ochoa-Gondar O. Antipneumococcal Vaccination in COPD Patients, Chronic Obstructive Pulmonary Disease-Current Concepts and Practice. Accessed date: 27 Mart 2013. Available from: http://cdn. intechopen.com/pdfs/30179/InTechAntipneumococcal_ vaccination_in_copd_patients.pdf 10. Müllerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med 2012
  10. Rello J, Rodriguez A, Torres A, Roig J, Sole-Violan J, Garnacho-Montero J, et al. Implications of COPD in patients admitted to the intensive care unit by communityacquired pneumonia. Eur Respir J 2006
  11. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respi